oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2018-17-2-71-81oncotomsk-718Research ArticleОБЗОРЫREVIEWSДИАГНОСТИЧЕСКИЕ РАДИОФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ОСНОВЕ ПРОИЗВОДНЫХ ГЛЮКОЗЫ В СОВРЕМЕННОЙ ОНКОЛОГИЧЕСКОЙ ПРАКТИКЕRADIOPHARMACEUTICALS BASED ON THE GLUCOSE DERIVATIVES FOR TUMOR DIAGNOSIShttps://orcid.org/0000-0002-4568-1781ЗельчанР. В.ZeltchanR. V.

кандидат медицинских наук, врач отделения радионуклидной диагностики, Научноисследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской акаде‑ мии наук (г. Томск, Россия)

SPIN-код: 2255-5282

Researcher ID: C-8597-2012

Scopus Author ID: 56901332100

MD, PhD, Radiologist, Nuclear Medicine Department, Cancer Research Institute, Tomsk National Research Medi‑ cal Center, Russian Academy of Sciences (Tomsk, Russia)

Researcher ID: C-8597-2012

Scopus Author ID: 56901332100

r.zelchan@yandex.ruhttps://orcid.org/0000-0002-5840-3625МедведеваА. А.MedvedevaA. A.

кандидат медицинских наук, старший научный сотрудник отделения радионуклидной диагностики, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук (г. Томск, Россия)

SPIN-код: 9110-1730

Researcher ID: D-7455-2012

Scopus Author ID: 57188995343

 

MD, PhD, Senior Researcher, Nuclear Medicine Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russia)

Researcher ID: D-7455-2012.

Scopus Author ID: 57188995343

medvedeva@tnimc.ruhttps://orcid.org/0000-0001-6351-6408СинилкинИ. Г.SinilkinI. G.

кандидат медицинских наук, старший научный сотрудник отделения радионуклидной диагностики, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук (г. Томск, Россия)

SPIN-код: 7254-3474

Researcher ID: С-92822012

Scopus Author ID: 6506263379

 

MD, PhD, Senior Researcher, Nuclear Medicine Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russia)

Researcher ID: С-9282-2012

Scopus Author ID: 6506263379

sinilkinig@oncology.tomsk.ruhttps://orcid.org/0000-0001-5281-7758БрагинаО. Д.BraginaO. V.

кандидат медицинских наук, младший научный сотрудник отделения радионуклидной диагностики, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук (г. Томск, Россия)

SPIN-код: 7961-5918

Researcher ID: E-9732-2017

Scopus Author ID: 57190936256

MD, PhD, Researcher, Nuclear Medicine Department, Cancer Research Institute, Tomsk National Research Medi‑ cal Center, Russian Academy of Sciences (Tomsk, Russia)

Researcher ID: E-9732-2017

Scopus Author ID: 57190936256

rungis@mail.ruhttps://orcid.org/0000-0002-5524-9546ЧерновВ. И.ChernovV. J.

доктор медицинских наук, профессор, заместитель директора по научной работе и инноваци‑ онной деятельности, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук (г. Томск, Россия)

SPIN-код: 6301-3612

Researcher ID: B-6789-2016

Scopus Author ID: 7201429550

 

MD, DSc,Professor, Deputy Director for Science and Innovation, Head of Nuclear Medicine Department, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Tomsk, Russia)

Researcher ID: B-6789-2016

Scopus Author ID: 7201429550

chernov@tnimc.ruНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, г. ТомскРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, TomskRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук, г. Томск; Федеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский Томский политехнический университет», г. ТомскРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk; National Research Tomsk Polytechnic University, TomskRussian Federation2018080520181727181Copyright © Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Чернов В.И., 20182018Зельчан Р.В., Медведева А.А., Синилкин И.Г., Брагина О.Д., Чернов В.И.Zeltchan R.V., Medvedeva A.A., Sinilkin I.G., Bragina O.V., Chernov V.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/718

Цель исследования – анализ имеющихся на сегодняшний день литературных данных об эффективности применения диагностических радиофармацевтических препаратов на основе меченных радиоактивными изотопами производных глюкозы в визуализации злокачественных новообразований различных локализаций. Материал и методы. Поиск соответствующих источников производился в системах Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health и РИНЦ, включались публикации с 2000 по 2016 г. Из 900 источников в обзор были включены 58 наиболее полных и фундаментальных трудов в области ядерной медицины. Результаты. В настоящее время в онкологии достаточно широко используется диагностический радиофармацевтический препарат на основе меченной фтором-18 производной глюкозы – 18F-дезоксиглюкоза (18F-ФДГ). Применение указанного радиофармпрепарата доказало свою эффективность в визуализации злокачественных новообразований различных локализаций, оценке распространенности опухолевого процесса и оценке эффективности проводимого лечения. При этом в мире идет поиск новых, более специфичных и эффективных радиофармпрепаратов для визуализации опухолевой ткани. Достаточно много трудов посвящено разработке радиофармацевтических препаратов на основе меченных технецием-99m производных глюкозы для визуализации опухолевой ткани. Значительных результатов в этой области достигли отечественные исследователи, разрабатывающие оригинальные препараты для однофотонной эмиссионной компьютерной томографии. Заключение. Несмотря на широкое распространение в мире технологий позитронно-эмиссионной томографии, доказавшей свою эффективность, у специалистов по- прежнему остается большой интерес к радиофармацевтическим препаратам на основе технеция-99m. Анализ литературы свидетельствует о том, что появление диагностического радиофармацевтического препарата на основе меченной технецием-99m производной глюкозы поможет повысить доступность методов ядерной медицины и их эффективность.

The purpose of the study was to review available literature on the efficacy of radiopharmaceuticals based on glucose derivatives labeled with radioactive isotopes for detection of various cancers. Material and methods. A systematic literature review was performed using the Scopus, Web of Science, MedLine, Cochrane Library, EMBASE, and Global Health databases from 2000 to 2016. Out of 900 papers in the field of nuclear medicine, 58 were included into the review. Results. 18F-fluoro-2-deoxy-D-glucose (18F-FDG) has been approved to be a powerful imaging tool for the detection of various cancers as well as for the assessment of tumor extent and therapy response. There is a continuous search for new more specific and effective radiopharmaceuticals for visualization of tumor tissue. Many studies are devoted to the development of radiopharmaceuticals based on technetium-99m labeled glucose derivatives for tumor visualization. Russian researches have made a significant progress in the development of imaging agents for single-photon emission computed tomography. Conclusion. Despite the widespread use of positron emission tomography technologies, which have proved to be effective, the specialists still have a great interest in radiopharmaceuticals based on technetium-99m. The literature review suggests that the emergence of a diagnostic radiopharmaceutical based on technetium-99m labeled glucose derivative will help to improve the availability of nuclear medicine methods and their effectiveness.

радионуклидная диагностикарадиофармпрепаратыпроизводные глюкозытехнеций-99mфтордезоксиглюкозаradionuclide diagnosisradiopharmaceuticalsglucose derivativestechnetium-99mfluorodeoxyglucoseИсточником финансирования исследования является Федеральная целевая программа «Исследования и разработки по приоритетным направлениям развития научно-технологического комплекса России на 2014–2020 годы» Соглашение о предоставлении субсидии от 23.10.2017, 14.601.21.0015 между Министерством образования и науки Российской Федерации и Томским НИМЦ, на выполнение научно-исследовательской работы по теме: «Разработка прогноза реализации приоритета научно-технологического развития, определенного пунктом 20в «Переход к персонализированной медицине, высокотехнологичному здравоохранению и технологиям здоровьесбережения, в том числе за счет рационального применения лекарственных препаратов (прежде всего антибактериальных)» Стратегии научно-технологического развития Российской Федерации». Уникальный идентификатор работ (проекта) RFMEF160117X0015. Идентификатор государственного соглашения 0000000007417PE10002ReferencesНиколаев А.Я. Биологическая химия. М., 2004. 566.Nikolaev A.Ya. Biological chemistry. Moscow, 2004; 566. [in Russian]Bertagna F., Treglia G., Baiocchi G. L., Giubbini R. F18 FDG PET/ CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature. Jpn J Radiol. 2013; 31 (4): 229–36. doi: 10.1007/ s11604 012 0176 2.Bertagna F., Treglia G., Baiocchi G. L., Giubbini R. F18 FDG PET/ CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature. Jpn J Radiol. 2013; 31 (4): 229–36. doi: 10.1007/ s11604 012 0176 2.Pauwels E.K.J., Coumou A.W., Kostkiewicz M., Kairemo K. [18F] Fluoro 2 Deoxy D Glucose Positron Emission Tomography/ Computed Tomography Imaging in Oncology: Initial Staging and Evalu ation of Cancer Therapy. Med Princ Pract. 2013; 22 (5): 427–37. doi: 10.1159/000346303.Pauwels E.K.J., Coumou A.W., Kostkiewicz M., Kairemo K. [18F] Fluoro 2 Deoxy D Glucose Positron Emission Tomography/ Computed Tomography Imaging in Oncology: Initial Staging and Evalu ation of Cancer Therapy. Med Princ Pract. 2013; 22 (5): 427–37. doi: 10.1159/000346303.Zhang L., Wang Y., Lei J., Tian J., Zhai Y. Dual time point 18FDG PET/CT versus single time point 18FDG PET/CT for the differential diagnosis of pulmonary nodules: a meta analysis. Acta Radiol. 2013 Sep; 54 (7): 770–7. doi: 10.1177/0284185113481594.Zhang L., Wang Y., Lei J., Tian J., Zhai Y. Dual time point 18FDG PET/CT versus single time point 18FDG PET/CT for the differential diagnosis of pulmonary nodules: a meta analysis. Acta Radiol. 2013 Sep; 54 (7): 770–7. doi: 10.1177/0284185113481594.Groheux D., Giacchetti S., Moretti J.L., Porcher R., Espié M., Lehmann-Che J., de Roquancourt A., Hamy A.S., Cuvier C., Vercellino L., Hindié E. Correlation of high 18F FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011 Mar; 38 (3): 426–35. doi: 10.1007/s00259 010 1640 9.Groheux D., Giacchetti S., Moretti J.L., Porcher R., Espié M., Lehmann-Che J., de Roquancourt A., Hamy A.S., Cuvier C., Vercellino L., Hindié E. Correlation of high 18F FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011 Mar; 38 (3): 426–35. doi: 10.1007/s00259 010 1640 9.Kubota K., Matsuzawa T., Amemiya A., Kondo M., Fujiwara T., Watanuki S., Ito M., Ido T.J. Imaging of breast cancer with [18F]fluoro deoxyglucose and positron emission tomogram. J Comput Assist Tomogr. 1989 Nov Dec; 13 (6): 1097–8.Kubota K., Matsuzawa T., Amemiya A., Kondo M., Fujiwara T., Watanuki S., Ito M., Ido T.J. Imaging of breast cancer with [18F]fluoro deoxyglucose and positron emission tomogram. J Comput Assist Tomogr. 1989 Nov Dec; 13 (6): 1097–8.Тицкая А.А., Чернов В.И., Слонимская Е.М., Синилкин И.Г. Сравнение результатов маммосцинтиграфии с 99mТс технетрилом в планарном и томографическом режимах. Медицинская радиология и радиационная безопасность. 2008; 53 (5): 51–60.Titskaya A.A., Chernov V.I., Slonimskaya E.M., Sinilkin I.G. Com parison of the results of mammoscintigraphy with 99mTc technetril in planar and tomographic regimes. Medical radiology and radiation safety. 2008. 53 (5): 51–60. [in Russian]Koolen B.B., Valdés Olmos R.A., Elkhuizen P.H., Vogel W.V., Vrancken Peeters, M.-J.T.F.D., Rodenhuis S., Rutgers E.J.T. Locoregional lymph node involvement on 18F FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat. 2012 Aug; 135 (1): 231–40. doi: 10.1007/s10549 012 2179 1.Koolen B.B., Valdés Olmos R.A., Elkhuizen P.H., Vogel W.V., Vrancken Peeters, M.-J.T.F.D., Rodenhuis S., Rutgers E.J.T. Locoregional lymph node involvement on 18F FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat. 2012 Aug; 135 (1): 231–40. doi: 10.1007/s10549 012 2179 1.Riegger C., Herrmann J., Nagarajah J., Hecktor J., Kuemmel S., Otterbach F., Heusner T.A. Whole body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012 May; 39 (5): 852–63. doi: 10.1007/ s00259 012 2077 0.Riegger C., Herrmann J., Nagarajah J., Hecktor J., Kuemmel S., Otterbach F., Heusner T.A. Whole body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012 May; 39 (5): 852–63. doi: 10.1007/ s00259 012 2077 0.Allal A.S., Dulguerov P., Allaoua M., Haenggeli C.A., El Ghazi E.A., Lehmann W., Slosman D.O. Standardized Uptake Value of 2 [18F] Fluoro 2 Deoxy D Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy. J Clin Oncol. 2002; 20 (5): 1398–1404. doi:10.1200/jco.20.5.1398.Allal A.S., Dulguerov P., Allaoua M., Haenggeli C.A., El Ghazi E.A., Lehmann W., Slosman D.O. Standardized Uptake Value of 2 [18F] Fluoro 2 Deoxy D Glucose in Predicting Outcome in Head and Neck Carcinomas Treated by Radiotherapy With or Without Chemotherapy. J Clin Oncol. 2002; 20 (5): 1398–1404. doi:10.1200/jco.20.5.1398.Чернов В.И., Зельчан Р.В., Тицкая А.А., Синилкин И.Г., Чижевская С.Ю., Суркова П.В., Чойнзонов Е.Л. Применение гамма сцинтиграфии с 99mTc технетрилом в комплексной диагностике и оценке эффективности неоадъювантной химиотерапии злокачественных опухолей гортани и гортаноглотки. Медицинская радиология и радиационная безопасность. 2011; 56 (2): 38–43.Chernov V.I., Zel’chan R.V., Titskaya A.A., Sinilkin I.G., Chizhevskaya S.Yu., Surkova P.V., Choinzonov E.L. The use of gamma scintigraphy with 99mTc technetril in the complex diagnosis and evaluation of the efficacy of neoadjuvant chemotherapy for malignant tumors of the larynx and laryngopharynx. Medical radiology and radiation safety. 2011; 56 (2): 38–43. [in Russian]Gao S., Li S., Yang X., Tang Q. 18FDG PET CT for distant me tastases in patients with recurrent head and neck cancer after definitive treatment. A meta analysis. Oral Oncol. 2014 Mar; 50 (3): 163–7. doi: 10.1016/j.oraloncology.2013.12.002.Gao S., Li S., Yang X., Tang Q. 18FDG PET CT for distant me tastases in patients with recurrent head and neck cancer after definitive treatment. A meta analysis. Oral Oncol. 2014 Mar; 50 (3): 163–7. doi: 10.1016/j.oraloncology.2013.12.002.Lapela M., Grénman R., Kurki T., Joensuu H., Leskinen S., Lindholm P., Haaparanta M., Ruotsalainen U., Minn H. Head and neck cancer: detection of recurrence with PET and 2 [F18] fluoro 2 deoxy D glucose. Radiology. 1995; 197 (1): 205–211. doi:10.1148/radiology.197.1.7568825Lapela M., Grénman R., Kurki T., Joensuu H., Leskinen S., Lindholm P., Haaparanta M., Ruotsalainen U., Minn H. Head and neck cancer: detection of recurrence with PET and 2 [F18] fluoro 2 deoxy D glucose. Radiology. 1995; 197 (1): 205–211. doi:10.1148/ radiology.197.1.7568825Carlson E.R., Schaefferkoetter J., Townsend D., McCoy J.M., Campbell P.D., Long M. The Use of Multiple Time Point Dynamic Positron Emission Tomography/Computed Tomography in Patients With Oral/Head and Neck Cancer Does Not Predictably Identify Metastatic Cervical Lymph Nodes. J Oral Maxillofac Surg. 2013 Jan; 71 (1): 162–77. doi: 10.1016/j. joms.2012.03.028.Carlson E.R., Schaefferkoetter J., Townsend D., McCoy J.M., Campbell P.D., Long M. The Use of Multiple Time Point Dynamic Positron Emission Tomography/Computed Tomography in Patients With Oral/Head and Neck Cancer Does Not Predictably Identify Metastatic Cervical Lymph Nodes. J Oral Maxillofac Surg. 2013 Jan; 71 (1): 162–77. doi: 10.1016/j. joms.2012.03.028.Javery O., Shyn P., Mortele K. FDG PET or PET/CT in patients with pancreatic cancer: when does it add to diagnostic CT or MRI? Clinical Imaging. 2013; 37 (2): 295–301. doi:10.1016/j.clinimag.2012.07.005.Javery O., Shyn P., Mortele K. FDG PET or PET/CT in patients with pancreatic cancer: when does it add to diagnostic CT or MRI? Clinical Imaging. 2013; 37 (2): 295–301. doi:10.1016/j.clinimag.2012.07.005Xu H.-X., Chen T., Wang W.-Q., Wu C.-T., Liu C., Long J., Yu X.-J. Metabolic tumour burden assessed by 18F FDG PET/CT associated with serum CA19 9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 2014 Jun; 41 (6): 1093–102. doi: 10.1007/ s00259 014 2688 8.Xu H.-X., Chen T., Wang W.-Q., Wu C.-T., Liu C., Long J., Yu X.-J. Metabolic tumour burden assessed by 18F FDG PET/CT associated with serum CA19 9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging. 2014 Jun; 41 (6): 1093–102. doi: 10.1007/ s00259 014 2688 8.Kim Y.-J., Yun M., Lee W.J., Kim K.S., Lee J.D. Usefulness of 18 F FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003; 30 (11): 1467–1472. doi:10.1007/s00259 003 1297 8Kim Y.-J., Yun M., Lee W.J., Kim K.S., Lee J.D. Usefulness of 18 F FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003; 30 (11): 1467–1472. doi:10.1007/s00259 003 1297 8Sun G., Tian J., Gorospe E.C., Johnson G.B., Hunt C.H., Lutzke L.S., Wang K.K. Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. J Gastroen terol Hepatol. 2013; 28 (6): 975–981. doi:10.1111/jgh.12148.Sun G., Tian J., Gorospe E.C., Johnson G.B., Hunt C.H., Lutzke L.S., Wang K.K. Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. J Gastroenterol Hepatol. 2013; 28 (6): 975–981. doi:10.1111/jgh.12148.Kamel I.R., Cohade C., Neyman E., Fishman E.K., Wahl R.L. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdominal Imaging. 2004; 29 (6): 663–668. doi:10.1007/s00261 003 0163 2.Kamel I.R., Cohade C., Neyman E., Fishman E.K., Wahl R.L. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdominal Imaging. 2004; 29 (6): 663–668. doi:10.1007/s00261 003 0163 2.Bonanni L., de’ Liguori Carino N., Deshpande R., Ammori B.J., Sherlock D.J., Valle J.W., O’Reilly D.A. A comparison of diagnostic imag ing modalities for colorectal liver metastases. Eur J Surg Oncol (EJSO). 2014; 40 (5): 545–550. doi:10.1016/j.ejso.2013.12.023Bonanni L., de’ Liguori Carino N., Deshpande R., Ammori B.J., Sherlock D.J., Valle J.W., O’Reilly D.A. A comparison of diagnostic imag ing modalities for colorectal liver metastases. Eur J Surg Oncol (EJSO). 2014; 40 (5): 545–550. doi:10.1016/j.ejso.2013.12.023Stone W.Z., Wymer D.C., Canales B.K. Fluorodeoxyglucose Pos itron Emission Tomography/Computed Tomography Imaging for Adrenal Masses in Patients with Lung Cancer: Review and Diagnostic Algorithm. J Endourol. 2014 Jan; 28 (1): 104–11. doi: 10.1089/end.2013.0380.Stone W.Z., Wymer D.C., Canales B.K. Fluorodeoxyglucose Pos itron Emission Tomography/Computed Tomography Imaging for Adrenal Masses in Patients with Lung Cancer: Review and Diagnostic Algorithm. J Endourol. 2014 Jan; 28 (1): 104–11. doi: 10.1089/end.2013.0380.Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Ow-ens D.K. Accuracy of Positron Emission Tomography for Diagnosis of Pulmonary Nodules and Mass Lesions. JAMA. 2001; 285 (7): 914–24. doi:10.1001/jama.285.7.914.Gould M.K., Maclean C.C., Kuschner W.G., Rydzak C.E., Ow-ens D.K. Accuracy of Positron Emission Tomography for Diagnosis of Pulmonary Nodules and Mass Lesions. JAMA. 2001; 285 (7): 914–24. doi:10.1001/jama.285.7.914.Tandberg D.J., Gee N.G., Chino J.P., D’Amico T.A., Ready N.E., Coleman R.E., Kelsey C.R. Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? J Thor Cardiovasc Surg. 2013; 146 (4): 796–801. doi:10.1016/j.jtcvs.2013.05.027Tandberg D.J., Gee N.G., Chino J.P., D’Amico T.A., Ready N.E., Coleman R.E., Kelsey C.R. Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? J Thor Cardiovasc Surg. 2013; 146 (4): 796–801. doi:10.1016/j.jtcvs.2013.05.027Hoh C., Figlin R., Belldegrun A. Evaluation of renal cell carcinoma with whole body FDG PET. J Nucl Med. 1996; 37: 141–147.Hoh C., Figlin R., Belldegrun A. Evaluation of renal cell carcinoma with whole body FDG PET. J Nucl Med. 1996; 37: 141–147.Ramdave S., Thomas G.W., Berlangieri S.U., Bolton D.M., Davis I., Danguy H.T., Macgregor D., Scott A.M. Clinical role of F 18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2001; 166: 825–830.Ramdave S., Thomas G.W., Berlangieri S.U., Bolton D.M., Davis I., Danguy H.T., Macgregor D., Scott A.M. Clinical role of F 18 fluorode oxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2001; 166: 825–830.Aide N., Cappele O., Bottet P., Bensadoun H., Regeasse A., Comoz F., Agostini D. Efficiency of [18F] FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003; 30: 1236–45.Aide N., Cappele O., Bottet P., Bensadoun H., Regeasse A., Comoz F., Agostini D. Efficiency of [18F] FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003; 30: 1236–45.Kang D.E., White R.L., Zuger J.H., Sasser H.C., Teigland C.M. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004; 171: 1806–1809.Kang D.E., White R.L., Zuger J.H., Sasser H.C., Teigland C.M. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004; 171: 1806–1809.Seto E., Segall G.M., Terris M.K. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology. 2000; 55: 286.Seto E., Segall G.M., Terris M.K. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan. Urology. 2000; 55: 286.Albers P., Bender H., Yilmaz H., Schoeneich G., Biersack H.J., Mueller S.C. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology. 1999; 53: 808–811.Albers P., Bender H., Yilmaz H., Schoeneich G., Biersack H.J., Mueller S.C. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology. 1999; 53: 808–811.Bajorin D.F., Herr H., Motzer R.J., Bosl G.J. Current perspectives on the role of adjunctive surgery in combined modality treatment for pa tients with germ cell tumors. Semin Oncol. 1992; 19: 148–158.Bajorin D.F., Herr H., Motzer R.J., Bosl G.J. Current perspectives on the role of adjunctive surgery in combined modality treatment for pa tients with germ cell tumors. Semin Oncol. 1992; 19: 148–158.Cremerius U., Effert P.J., Adam G., Sabri O., Zimmy M., Wagenknecht G., Jakse G., Buell U. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med. 1998; 39: 815–822.Cremerius U., Effert P.J., Adam G., Sabri O., Zimmy M., Wagenknecht G., Jakse G., Buell U. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med. 1998; 39: 815–822.Kühnel G., Horn L.C., Fischer U., Hesse S., Seese A., Georgi P., Kluge R. 18F FDG positronen Emissions Tomographie bei Zervixkarzi nom: Erste Ergebnisse. Zbl Gynacol. 2001; 4: 123.Kühnel G., Horn L.C., Fischer U., Hesse S., Seese A., Georgi P., Kluge R. 18F FDG positronen Emissions Tomographie bei Zervixkarzi nom: Erste Ergebnisse. Zbl Gynacol. 2001; 4: 123.Jang H.J., Lee K.H., Kim Y.H. The role PET for predicting prog nosis in squamous cell type uterine cervical carcinoma patients. J. Nucl. Med. 2002; 43 (3): 28P.Jang H.J., Lee K.H., Kim Y.H. The role PET for predicting prog nosis in squamous cell type uterine cervical carcinoma patients. J. Nucl. Med. 2002; 43 (3): 28P.Bats A.S., Hugonnet F., Huchon C., Bensaid C., Pierquet-Ghazzar N., Faraggi M., Lécuru F. Prognostic significance of mediastinal 18F FDG uptake in PET/CT in advanced ovarian cancer. Eur J Nucl Med Mol Imag ing. 2012 Mar; 39 (3): 474–80. doi: 10.1007/s00259 011 1984 9.Bats A.S., Hugonnet F., Huchon C., Bensaid C., Pierquet-Ghazzar N., Faraggi M., Lécuru F. Prognostic significance of mediastinal 18F FDG uptake in PET/CT in advanced ovarian cancer. Eur J Nucl Med Mol Imag ing. 2012 Mar; 39 (3): 474–80. doi: 10.1007/s00259 011 1984 9.Chang T.C., Law K.S., Hong J.H., Lai C.H., Ng K.K., Hsueh S., See L.C., Chang Y.C., Tsai C.S., Chou H.H., Huang K.G., Liou J.D., Lin C.T., Chao A., Chen M.Y., Wu T.I., Ma S.Y., Yen T.C. Positron emission tomogra phy for unexplained elevation of serum squamous cell carcinoma antigen levels during follow up for patients with cervical malignancies: a phase II study. Cancer. 2004; 101: 164–171.Chang T.C., Law K.S., Hong J.H., Lai C.H., Ng K.K., Hsueh S., See L.C., Chang Y.C., Tsai C.S., Chou H.H., Huang K.G., Liou J.D., Lin C.T., Chao A., Chen M.Y., Wu T.I., Ma S.Y., Yen T.C. Positron emission tomogra phy for unexplained elevation of serum squamous cell carcinoma antigen levels during follow up for patients with cervical malignancies: a phase II study. Cancer. 2004; 101: 164–171.Zhao Q., Feng Y., Mao X., Qie M. Prognostic value of fluorine 18 fluorodeoxyglucose positron emission tomography or PET computed tomography in cervical cancer: A meta analysis. Int J Gynecol Cancer. 2013 Sep; 23 (7): 1184–90. doi: 10.1097/IGC.0b013e31829ee012.Zhao Q., Feng Y., Mao X., Qie M. Prognostic value of fluorine 18 fluorodeoxyglucose positron emission tomography or PET computed tomography in cervical cancer: A meta analysis. Int J Gynecol Cancer. 2013 Sep; 23 (7): 1184–90. doi: 10.1097/IGC.0b013e31829ee012.Belhocine T., De Barsy C., Hustinx R., Willems-Foidart J. Useful ness of (18)F FDG PET in the post therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2002; 29: 1132–1139.Belhocine T., De Barsy C., Hustinx R., Willems-Foidart J. Useful ness of (18)F FDG PET in the post therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2002; 29: 1132–1139.Saga T., Higashi T., Ishimori T., Mamede M., Nakamoto Y., Mukai T., Fujita T., Togashi K., Yura S., Higuchi T., Kita M., Fujii S., Konishi J. Clinical value of FDG PET in the follow up of post operative patients with endometrial cancer. Ann Nucl Med. 2003; 17: 197–203.Saga T., Higashi T., Ishimori T., Mamede M., Nakamoto Y., Mukai T., Fujita T., Togashi K., Yura S., Higuchi T., Kita M., Fujii S., Konishi J. Clinical value of FDG PET in the follow up of post operative patients with endometrial cancer. Ann Nucl Med. 2003; 17: 197–203.Buchmann I., Reinhardt M., Elsner K., Bunjes D., Altehoefer C., Finke J., Moser E., Glatting G., Kotzerke J., Guhlmann C.A., Schirrmeister H., Reske S.N. 2 (Fluorine 18) fluoro 2 deoxy D glucose positron emission tomography in the detection and staging of malignant lymphoma. Cancer. 2001; 91: 889–899.Buchmann I., Reinhardt M., Elsner K., Bunjes D., Altehoefer C., Finke J., Moser E., Glatting G., Kotzerke J., Guhlmann C.A., Schirrmeister H., Reske S.N. 2 (Fluorine 18) fluoro 2 deoxy D glucose positron emission tomography in the detection and staging of malignant lymphoma. Cancer. 2001; 91: 889–899.Gallamini A., Barrington S.F., Biggi A., Chauvie S., Kostakoglu L., Gregianin M., Seymour J.F. The predictive role of interim Positron Emis sion Tomography on Hodgkin lymphoma treatment outcome is confirmed using the 5 point scale interpretation criteria. Haematologica. 2014; 99: 1107–1113.Gallamini A., Barrington S.F., Biggi A., Chauvie S., Kostakoglu L., Gregianin M., Seymour J.F. The predictive role of interim Positron Emission Tomography on Hodgkin lymphoma treatment outcome is confirmed using the 5 point scale interpretation criteria. Haematologica. 2014; 99: 1107–1113.Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri A.J., Zinzani P.L., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella A.M., Santoro A., Musto P., Federico M. The use of FDG PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013 Aug; 24 (8): 2108–12. doi: 10.1093/annonc/mdt137.Luminari S., Biasoli I., Arcaini L., Versari A., Rusconi C., Merli F., Spina M., Ferreri A.J., Zinzani P.L., Gallamini A., Mastronardi S., Boccomini C., Gaidano G., D’Arco A.M., Di Raimondo F., Carella A.M., antoro A., Musto P., Federico M. The use of FDG PET in the initial staging of 142 patients with follicular lymphoma: A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013 Aug; 24 (8): 2108–12. doi: 10.1093/annonc/mdt137.Pellegrini C., Argnani L., Broccoli A., Stefoni V., Derenzini E., Gandolfi L., Casadei B., Maglie R., Pileri S., Zinzani P.L. Prognostic Value of Interim Positron Emission Tomography in Patients With Peripheral T Cell Lymphoma. Oncologist. 2014 Jul; 19 (7): 746–50. doi: 10.1634/ theoncologist.2013 0463.Pellegrini C., Argnani L., Broccoli A., Stefoni V., Derenzini E., Gandolfi L., Casadei B., Maglie R., Pileri S., Zinzani P.L. Prognostic Value of Interim Positron Emission Tomography in Patients With Peripheral T Cell Lymphoma. Oncologist. 2014 Jul; 19 (7): 746–50. doi: 10.1634/ theoncologist.2013 0463.Pakos E.E., Fotopoulos A.D., Ioannidis J.P. A FDG PET for evalu ation of bone marrow infiltration in staging of lymphoma a meta analysis. J Nucl Med. 2005; 46: 958–963.Pakos E.E., Fotopoulos A.D., Ioannidis J.P. A FDG PET for evaluation of bone marrow infiltration in staging of lymphoma a meta analysis. J Nucl Med. 2005; 46: 958–963.Torizuka T., Nakamura F., Kanno T., Futatsubashi M., Yoshikawa E., Okada H., Kobayashi M., Ouchi Y. Early therapy monitoring with FDG PET in aggressive non Hodgkin’s lymphoma and Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2004; 31: 312–228.Torizuka T., Nakamura F., Kanno T., Futatsubashi M., Yoshikawa E., Okada H., Kobayashi M., Ouchi Y. Early therapy monitoring with FDG PET in aggressive non Hodgkin’s lymphoma and Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2004; 31: 312–228.Juweid M.E., Wiseman G.A., Vose J.M., Ritchie J.M., Menda Y., Wooldridge J.E., Mottaghy F.M., Rohren E.M., Blumstein N.M., Stolpen A., Link B.K., Reske S.N., Graham M.M., Cheson B.D. Response assess ment of aggressive non Hodgkin’s lymphoma by integrated international workshop criteria and Fluorine 18F Fuoredeoxyglucose positron emission tomography. J Med Oncol. 2005; 23: 4652–61.Juweid M.E., Wiseman G.A., Vose J.M., Ritchie J.M., Menda Y., Wooldridge J.E., Mottaghy F.M., Rohren E.M., Blumstein N.M., Stolpen A., Link B.K., Reske S.N., Graham M.M., Cheson B.D. Response assess ment of aggressive non Hodgkin’s lymphoma by integrated international workshop criteria and Fluorine 18F Fuoredeoxyglucose positron emission tomography. J Med Oncol. 2005; 23: 4652–61.Biggi A., Gallamini A., Chauvie S., Hutchings M., Kostakoglu L., Gregianin M., Meignan M., Malkowski B., Hofman M.S., Barrington S.F. International validation study for interim PET in ABVD treated, advanced stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013 May; 54 (5): 683–90. doi: 10.2967/ jnumed.112.110890.Biggi A., Gallamini A., Chauvie S., Hutchings M., Kostakoglu L., Gregianin M., Meignan M., Malkowski B., Hofman M.S., Barrington S.F. International validation study for interim PET in ABVD treated, advanced stage Hodgkin lymphoma: Interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013 May; 54 (5): 683–90. doi: 10.2967/ jnumed.112.110890.Charronneau E., Mathieu J-P., Morin C. Large scale synthesis and radiolabelling of 6 deoxy 6 iodo D glucose (6 DIG). Appl Radioat Isot. 1998; 49: 1605–1607.Charronneau E., Mathieu J-P., Morin C. Large scale synthesis and radiolabelling of 6 deoxy 6 iodo D glucose (6 DIG). Appl Radioat Isot. 1998; 49: 1605–1607.Matte G., Adam M., Lyster D. Biological evaluation of 2 fluoro 2 [123I]Iodo mannose (FIM). Nucl Med Biol. 2001; 28 (6): 679–682.Matte G., Adam M., Lyster D. Biological evaluation of 2 fluoro 2 [123I]Iodo mannose (FIM). Nucl Med Biol. 2001; 28 (6): 679–682.Brunet-Desruet M.D., Ghezzi C., Morin C., Comet M., Fagret D. Biological Evaluation of Two Iodine 123 Labeled D Glucose Acetals Prepared as Glucose Transporter. Nucl Med. Biol. 1998; 25 (5): 473–80.Brunet-Desruet M.D., Ghezzi C., Morin C., Comet M., Fagret D. Biological Evaluation of Two Iodine 123 Labeled D Glucose Acetals Prepared as Glucose Transporter. Nucl Med. Biol. 1998; 25 (5): 473–80.Чернов В.И., Кравчук Т.Л., Зельчан Р.В., Гольдберг В.Е. ЭКГ синхронизированная перфузионная томосцинтиграфия миокарда сChernov V.I., Kravchuk T.L., Zel’chan R.V., Gol’dberg V.E. ECG synchronized perfusion tomoscintigraphy of myocardium with 99mTc technetril in the assessment of acute and chronic cardiotoxicity of chemotherapeutic drugs. Medical radiology and radiation safety. 2012; 57 (4): 32–39. [in Russian]mTc технетрилом в оценке острой и хронической кардиотоксичности химиотерапевтических препаратов. Медицинская радиология и радиационная безопасность. 2012; 57c(4): 32–39.Hee-Kyung Lee, Dae-Hybk Moon, Jin-Sook Ryu. Radioisotope labeled complexes of glucose derivatives and kits for the preparation thereof. Patent United States Pub. No.: 2003/0120046 A. 2003 Jun 26.Hee-Kyung Lee, Dae-Hybk Moon, Jin-Sook Ryu. Radioisotope labeled complexes of glucose derivatives and kits for the preparation thereof. Patent United States Pub. No.: 2003/0120046 A. 2003 Jun 26.Ozker S.K., Collier B.D. Imaging methods and compositions. Patent United States Pub. No.: 06099822A. 2000.Ozker S.K., Collier B.D. Imaging methods and compositions. Patent United States Pub. No.: 06099822A. 2000.Chen Y., Huang Z.W., He L., Zheng S.L., Li J.L., Qin D.L. Synthesis and evaluation of a technetium 99m labeled diethylentriaminepentaacetate deoxyglucose complex 99mTc DTPA DG as a potential imaging modality for tumors. Appl Radiat Isot. 2006; 64 (3): 342–347.Chen Y., Huang Z.W., He L., Zheng S.L., Li J.L., Qin D.L. Synthesis and evaluation of a technetium 99m labeled diethylentriaminepentaacetate deoxyglucose complex 99mTc DTPA DG as a potential imaging modality for tumors. Appl Radiat Isot. 2006; 64 (3): 342–347.Cheng D., Rusckowski M., Wang Y.., Liu Y., Liu G., Liu X., Hnatowich D. A Brief Evaluation of Tumor Imaging in Mice with 99mTc glucarate Including a Comparison with 18F FDG. Curr Radiopharm. 2011; 4 (1): 5–9.Cheng D., Rusckowski M., Wang Y.., Liu Y., Liu G., Liu X., Hnatowich D. A Brief Evaluation of Tumor Imaging in Mice with 99mTc glucarate Including a Comparison with 18F FDG. Curr Radiopharm. 2011; 4 (1): 5–9.Welling M.M., Alberto R. Performance of a 99mTc labelled 1 thio beta D glucose 2,3,4,6 tetra acetate analogue in the detection of infections and tumours in mice: a comparison with [18F]FDG. Nucl Med Commun. 2010; 31 (3): 239–248.Welling M.M., Alberto R. Performance of a 99mTc labelled 1 thio beta D glucose 2,3,4,6 tetra acetate analogue in the detection of infections and tumours in mice: a comparison with [18F]FDG. Nucl Med Commun. 2010; 31 (3): 239–248.Yang D.J., Kim C.G., Schechter N.R., Azhdarinia A., Yu D.F., Oh C.S., Bryant J.L., Won J.J., Kim E.E., Podoloff D.A. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology. 2003; 226 (2): 465–473.Yang D.J., Kim C.G., Schechter N.R., Azhdarinia A., Yu D.F., Oh C.S., Bryant J.L., Won J.J., Kim E.E., Podoloff D.A. Imaging with 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology. 2003; 226 (2): 465–473.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Bragina O., Stasyuk E., Rogov A., Il’Ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium 99m labeled derivative of glucose for tumor diagnosis. 8th international scien tific conference on issues of physics and technology in science, industry and medicine. Tomsk, 01–03 June 2016. 012054.Zeltchan R., Medvedeva A., Sinilkin I., Chernov V., Bragina O., Stasyuk E., Rogov A., Il’Ina E., Larionova L., Skuridin V., Dergilev A. Experimental study of radiopharmaceuticals based on technetium 99m labeled derivative of glucose for tumor diagnosis. 8th international scientific conference on issues of physics and technology in science, industry and medicine. Tomsk, 01–03 June 2016. 012054.Chernov V.I., Medvedeva A.A., Sinilkin I.G., Zel’chan R.V., Bra-gina O.D., Skuridin V.S. Experience in the development of innovative radiopharmaceuticals in Tomsk Research Institute of Oncology. Siberian Journal of Oncology. 2015. Suppl. 2. 45–47. [in Russian]Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Скуридин В.С. Опыт разработки инновационных радиофармпрепартов в Томском НИИ онкологии. Сибирский онкологический журнал. 2015. Прил. 2. 45–47.Чернов В.И., Медведева А.А., Синилкин И.Г., Зельчан Р.В., Брагина О.Д., Скуридин В.С. Опыт разработки инновационных радиофармпрепартов в Томском НИИ онкологии. Сибирский онкологический журнал. 2015. Прил. 2. 45–47.

The authors declare that there are no conflicts of interest present.